TVB-2640
Phase 2Small molecule
TVB-2640 is one of 77 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
2
Indications
9
Total Trials
2
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Paraplatin
AAvyxa
Phase 3
Nizoral
WWim Janssens
Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
Lupron
Radiation Therapy Oncology GroupPhase 3
Trexall
Jazz PharmaceuticalsPreclinical
TVB-2640
SSagimet Biosciences Inc.
Phase 2
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Astrocytoma1 trial
TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT03032484·25 enrolled
Non-Small Cell Lung Carcinoma1 trial
Patients With Solid Tumors1 trial
4 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TVB-2640. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSagimet Biosciences Inc.